Cost-Effectiveness of Vaccinating Against Lyme Disease
Author Information
Author(s): Dimitri Prybylski
Primary Institution: University of Maryland School of Medicine
Hypothesis
Who should receive the newly licensed Lyme disease vaccine?
Conclusion
The study emphasizes the importance of considering post-Lyme syndrome in cost-effectiveness models for the Lyme disease vaccine.
Supporting Evidence
- One third to half of Lyme disease patients had post-Lyme syndrome symptoms years after the initial onset of disease.
- Longitudinal evaluations are needed to accurately estimate the duration of clinical sequelae.
Takeaway
This study looks at whether vaccinating against Lyme disease is worth the money, especially considering long-lasting symptoms some people have after getting Lyme disease.
Methodology
The authors examined cost savings from preventing Lyme disease sequelae and discussed the limitations of existing data.
Limitations
The study acknowledges the lack of validated cost-of-treatment data for generalized symptoms of Lyme disease.
Participant Demographics
Participants were individuals diagnosed with Lyme disease in the mid-1980s.
Want to read the original?
Access the complete publication on the publisher's website